Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
McKinsey
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: September 24, 2022

Patent: 10,030,270


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,030,270
Title:K-ras mutations and anti-EGFr antibody therapy
Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
Inventor(s): Freeman; Daniel (Newbury Park, CA), Juan; Todd (Newbury Park, CA), Radinsky; Robert (Thousand Oaks, CA)
Assignee: AMGEN, INC (Thousand Oaks, CA)
Application Number:13/523,174
Patent Claims:see list of patent claims

Details for Patent 10,030,270

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 See Plans and Pricing 2027-03-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKinsey
Moodys
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.